Partex NV and Sanofi Embark on AI-Driven Collaboration for Drug Out-Licensing

On March 14, 2024, Partex NV, a leading figure in AI-based drug discovery, announced its collaborative effort with the pharmaceutical conglomerate Sanofi. This partnership aims to employ Partex’s sophisticated AI technology to enhance the out-licensing portfolio of Sanofi. The collaboration builds on the success of a 2022 pilot project, focusing on expanding innovative methods to utilize Partex's AI division, Innoplexus, for identifying new indications for drugs within Sanofi's portfolio for out-licensing.

The endeavor seeks to meticulously explore indication expansion, prioritization, and conduct lab validation studies to find new opportunities for Sanofi's assets. Innoplexus will undertake the role of scanning, analyzing, and enriching several out-licensing asset candidates across various therapeutic domains, with the objective of repurposing or repositioning these assets with a focus on meeting patient needs.

Dr. Gunjan Bhardwaj, CEO of Partex, expressed his enthusiasm for the collaboration, highlighting the pivotal role of AI in discovering new potentials within Sanofi's out-licensing portfolio to address unmet medical needs. The project has initiated with the selection of the first three assets for AI predictions, geared to complete within 2024. This collaboration not only signifies a mutual commitment towards advancing healthcare but also includes prospective financial benefits for Partex, including an upfront cash payment and potential future incentives.